As the number of cases in the Ozempic MDL continues to rise, new filings are focusing on the claim that Novo Nordisk purposely minimized the risks of gastroparesis in its marketing. Plaintiffs’ lawyers argue that the company was aware of Ozempic’s effects on stomach motility but chose not to update the warning labels, fearing it might stop patients from starting or continuing the treatment.
The failure to address gastroparesis risks early in the drug’s release is expected to be a central issue in the litigation. As a result, many lawyers are now prioritizing cases specifically involving gastroparesis-related complications.